Remibrutinib Safe for Sjögren's in Phase 2

Results show the Bruton tyrosine kinase inhibitor has potential to become the first effective oral disease-modifying therapy for Sjögren syndrome.
Medscape Medical News

source https://www.medscape.com/viewarticle/983985?src=rss